Retatrutide: The Complete Guide to the Triple-Agonist (2026)

Retatrutide is an experimental once-weekly injection from Eli Lilly that has produced the largest weight loss of any obesity drug studied so far, by hitting three metabolic hormone receptors at once instead of one or two. In its first successful Phase 3 trial it lowered body weight by an average of up to 28.7%, but it is still investigational and not approved for sale anywhere.

If you have followed the GLP-1 story from semaglutide (Ozempic, Wegovy) to tirzepatide (Mounjaro, Zepbound), retatrutide is the next chapter, sometimes nicknamed "GLP-3," and the current frontrunner in our ranking of the best peptides for weight loss. This guide is the high-level map of the whole compound: what it is, how the triple-receptor mechanism actually works, what the trials measured for dosing and results, the side effects and safety picture, where it stands legally, and how people are getting it ahead of approval. Each section is a clear overview; for the deep-dive topics we point you to dedicated guides so this page stays a clean hub.

Key Takeaways

• Retatrutide (LY3437943) is a triple hormone-receptor agonist that activates the GLP-1, GIP, and glucagon receptors in one molecule, given as a once-weekly subcutaneous injection (NEJM, 2023).
• It is investigational, not FDA-approved. It is in the Phase 3 TRIUMPH program; the earliest realistic FDA decision is mid-to-late 2027 (analyst expectation, not a guarantee).
• Weight-loss results are the largest reported for an obesity drug. The Phase 2 trial showed up to ~24.2% mean weight loss at 48 weeks (12 mg), and Phase 3 TRIUMPH-1 reported 28.3% (an average 70.3 lb) at 80 weeks on 12 mg (NEJM, 2023; Eli Lilly / PR Newswire, 2026).
• Doses studied in trials run from a 2 mg start, titrated every ~4 weeks up to 4, 8, 9, or 12 mg once weekly, depending on the study. These are trial figures, not a dosing recommendation.
• Most side effects are gastrointestinal (nausea, diarrhea, vomiting, constipation) and tend to ease over time; a notable dysesthesia (skin-sensation) signal appeared at the 12 mg dose.
• No validated home-storage label exists. For handling, see our retatrutide storage and stability guide.

What is retatrutide?

Retatrutide is an investigational once-weekly injectable peptide developed by Eli Lilly that targets three metabolic hormone receptors at the same time. Its lab code is LY3437943, and because it adds a third receptor to the GLP-1/GIP combination, people informally call it a "triple agonist" or "GLP-3." It is being studied mainly for obesity, type 2 diabetes, and related metabolic conditions.

Chemically, retatrutide is a synthetic peptide, a short chain of amino acids engineered to mimic and combine the actions of three of the body's own gut and metabolic hormones. It is delivered as a subcutaneous injection (a small shot under the skin) once a week, the same delivery style used by semaglutide and tirzepatide (NEJM, "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial", 2023, retrieved 2026-06-15). If the idea of an injectable peptide is new to you, our what are peptides and how peptides work guides cover the basics first.

The single most important fact about retatrutide is its status: as of 2026 it is not approved by the FDA, EMA, or any other regulator. It exists only inside clinical trials and, separately, in an unapproved "research chemical" gray market. Everything else in this guide should be read through that lens.

Citation capsule. Retatrutide (LY3437943) is an investigational once-weekly subcutaneous peptide that acts as a single-molecule agonist of the GIP, GLP-1, and glucagon receptors. It is being developed by Eli Lilly, is in Phase 3 trials (the TRIUMPH program) for obesity and related conditions, and is not approved by any regulator. Source: NEJM (Jastreboff et al.), 2023; Eli Lilly, 2025-2026.

How does retatrutide work in the body?

Retatrutide works by switching on three hunger-and-metabolism hormone receptors at once, which reduces appetite, slows the gut, and increases the rate at which the body burns energy. That third lever, the glucagon receptor, is what separates it from earlier drugs and is thought to drive its extra fat loss.

In simple terms, the molecule imitates three natural gut and pancreatic hormones, so your brain receives stronger "I'm full" signals, your stomach empties more slowly, and your body's energy expenditure ticks up. You eat less without forcing willpower, and you may burn slightly more at rest. The three receptors it activates are GLP-1, GIP, and glucagon (NEJM, 2023, retrieved 2026-06-15).

Here is what each receptor contributes:

• GLP-1 (glucagon-like peptide-1): curbs appetite, slows stomach emptying, and improves blood-sugar control. This is the same receptor semaglutide targets.
• GIP (glucose-dependent insulinotropic polypeptide): works alongside GLP-1 on insulin and appetite; it is the second receptor tirzepatide added.
• Glucagon: the new ingredient. Glucagon-receptor activation can raise energy expenditure and promote fat breakdown in the liver, which is the leading explanation for why a triple agonist out-loses a dual agonist.

The mechanism deep-dive (receptor signaling, why glucagon is counterintuitive for a weight drug, and how it compares mechanistically to dual agonists) is its own topic. We keep it at overview level here and link out to how peptides work for the receptor-signaling foundations.

What is retatrutide used for?

Retatrutide is being studied mainly for obesity and overweight, with parallel trials in type 2 diabetes, knee osteoarthritis, obstructive sleep apnea, fatty liver disease, and cardiovascular risk. None of these are approved uses yet; they are the conditions the TRIUMPH Phase 3 program is testing.

The lead use is chronic weight management, where its three-receptor design has produced the field's largest trial weight loss. Beyond pure weight, Lilly's first successful Phase 3 trial (TRIUMPH-4) studied people who had both obesity and knee osteoarthritis, and reported meaningful knee-pain relief alongside weight loss, with WOMAC pain scores dropping by up to an average of 75.8% (Eli Lilly via Healio / HCPLive, "Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain", 2025, retrieved 2026-06-15).

The broader program is investigating a metabolic spread of conditions:

Because each of these is a distinct future spoke, we keep them brief here. The headline takeaway: retatrutide is being positioned not just as a weight drug but as a broad metabolic-disease drug.

What weight-loss results has retatrutide produced?

Retatrutide has produced the largest average weight loss of any obesity drug studied to date: up to roughly 24% in Phase 2 and up to 28-29% in its first Phase 3 readouts. Those numbers come from controlled trials of an investigational drug, not from real-world approved use.

The pivotal evidence arrived in two waves. In 2023, the New England Journal of Medicine published the Phase 2 obesity trial (Jastreboff et al.), which enrolled 338 adults and reported mean weight reductions of up to about 24.2% at 48 weeks on the 12 mg dose, the steepest curve the obesity field had seen (NEJM, "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial", 2023, retrieved 2026-06-15). Then in 2025-2026 the Phase 3 TRIUMPH program began to confirm it: TRIUMPH-4 (December 2025) reported up to 28.7% weight loss at 68 weeks in people with obesity and knee osteoarthritis, and TRIUMPH-1 (May 2026) reported 28.3% (an average 70.3 lb) at 80 weeks on 12 mg in a general obesity population (Eli Lilly / PR Newswire, "Lilly's triple agonist retatrutide delivered powerful weight loss in pivotal Phase 3 obesity trial", 2026, retrieved 2026-06-15).

A point worth keeping honest: the curve had not clearly plateaued by the end of the Phase 2 trial, which is part of why the results drew so much attention. Results also scale with dose and time, and individual outcomes vary widely. For realistic expectations and the difference between trial averages and everyday results, see peptides before and after.

What doses of retatrutide were studied in trials?

The doses studied in retatrutide trials start at 2 mg once weekly and are titrated upward every roughly four weeks toward target doses of 4, 8, 9, or 12 mg, depending on the study. These are trial protocols for an investigational drug, recorded here for accuracy, not as a dosing schedule for anyone to follow.

The Phase 2 trial tested once-weekly retatrutide at 1, 4, 8, and 12 mg, using starting doses of 2 mg or 4 mg titrated up over the study (NEJM, 2023, retrieved 2026-06-15). The Phase 3 program refined this: the pivotal study escalates from a 2 mg start every four weeks toward maintenance doses, with TRIUMPH-1 reporting results at 4, 9, and 12 mg once weekly (ClinicalTrials.gov, NCT05929066 (TRIUMPH-1), retrieved 2026-06-15; Eli Lilly / PR Newswire, 2026, retrieved 2026-06-15). The slow titration exists for one reason: to let the gut adjust and limit nausea.

The detailed titration ladder, dose-conversion math, and reconstitution volumes are a dedicated spoke. We cover only the trial framing here and link out to the full dosing and titration chart and, for mixing mechanics, the step-by-step reconstitution guide.

Our take: The "12 mg" headline gets all the attention, but the trials are clear that 4 mg and 8 mg already deliver dramatic weight loss. More is not automatically better when the trade-off is tolerability, which is exactly why every protocol titrates slowly rather than starting high.

What are the side effects of retatrutide?

The most common retatrutide side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation, which are usually mild-to-moderate and tend to ease as the body adjusts. A more distinctive signal seen at the highest dose is dysesthesia, an altered or "pins-and-needles" skin sensation.

These effects are typical of the GLP-1 drug class and are the main reason doses are titrated slowly. Across the trials, gastrointestinal symptoms drove most of the discontinuations, and the reported rate of people stopping due to side effects has generally fallen in a single-digit-to-mid-teens percentage range depending on dose and study (Noom / clinical summary, "Retatrutide Side Effects and Safety", 2025, retrieved 2026-06-15). In TRIUMPH-4, gastrointestinal effects were described as generally mild and infrequently caused discontinuation, while roughly 1 in 5 participants on the 12 mg dose experienced dysesthesia (Eli Lilly via HCPLive, "TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief", 2025, retrieved 2026-06-15).

A quick overview of what trials have reported:

• Very common (GI): nausea, diarrhea, vomiting, constipation, reduced appetite.
• Notable at high dose: dysesthesia (skin-sensation changes), more frequent at 12 mg.
• Watched / less common: transient increases in heart rate, and class-level concerns such as gallbladder issues and pancreatitis that apply across incretin drugs.
• Unknown: true long-term safety, because the drug is not yet approved and long-horizon data are still being collected.

This is the hub-level summary. A full side-effect deep-dive, including management strategies and the dysesthesia signal in detail, is a dedicated spoke: retatrutide side effects and how to manage them.

How does retatrutide compare to tirzepatide and semaglutide?

Retatrutide differs from semaglutide and tirzepatide by adding a third receptor (glucagon), and in trials it has produced larger average weight loss than either, though it is the only one of the three not yet approved. The trade-off is that the longest real-world safety record belongs to the approved drugs, not to retatrutide.

In rough terms: semaglutide (one receptor) produced about 15% mean weight loss in its pivotal obesity trial, tirzepatide (two receptors) reached roughly 20-22%, and retatrutide (three receptors) has reported up to ~24% in Phase 2 and ~28% in early Phase 3 (NEJM, 2023, retrieved 2026-06-15). Cross-trial comparisons like these are imperfect because the studies enrolled different populations and ran for different lengths, so treat the ladder as directional, not a head-to-head result.

The full comparison, including cost, availability, side-effect differences, and switching considerations, is its own spoke. We keep it short here to avoid overlapping that future article: see retatrutide vs tirzepatide and retatrutide vs semaglutide.

Is retatrutide safe and legal?

Retatrutide is not approved by any regulator, so there is no official safety determination and no legal pathway to buy it as an approved medicine; it is legal only inside clinical trials, while the products sold online are unapproved "research chemicals." That distinction matters more than any single safety statistic.

On safety, the trial data so far look promising on tolerability for an investigational drug, with mostly manageable gastrointestinal effects, but "promising in trials" is not the same as "established safe." Long-term safety, rare adverse events, and effects after stopping are still being studied, and no regulator has reviewed the full dossier (Eli Lilly via HCPLive, 2025, retrieved 2026-06-15). Because retatrutide has no approved label, nobody can responsibly call it "safe" for general use.

On legality, the situation mirrors other pre-approval peptides. It is not an FDA-approved drug, so it cannot be legally marketed or sold for human use in the United States. The vials people find online are typically labeled "for research use only, not for human consumption," which is a legal and quality gray zone, with no guarantee of identity, purity, or sterility. For the full legal picture and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: The single most common mistake we see is treating "in successful Phase 3 trials" as if it meant "approved and safe to use at home." It does not. Trial supervision, dose control, and monitoring are part of why those results looked good, and none of that comes in a research vial.

When could retatrutide be FDA-approved?

There is no approved-use date yet; analysts widely expect the earliest realistic FDA decision in mid-to-late 2027, assuming the remaining Phase 3 trials and the filing go smoothly. This is a projection from the trial timeline, not an official commitment from Lilly or the FDA.

The logic behind that estimate: the efficacy-core trials (TRIUMPH-1, TRIUMPH-2, and TRIUMPH-4) are reporting across 2026, which would let Eli Lilly assemble a New Drug Application with an earliest plausible filing around late 2026 (PR Newswire / Eli Lilly, 2026, retrieved 2026-06-15). A standard FDA review runs roughly ten months, which pushes a realistic decision into 2027; a priority review could shorten that. Several additional Phase 3 trials covering diabetes, sleep apnea, liver disease, and cardiovascular outcomes are also expected to read out through 2026 and beyond.

We hold the regulatory picture at overview level here, covering the per-trial readout dates, NDA mechanics, and EMA timing that matter most.

How do people obtain retatrutide before approval?

Because retatrutide is unapproved, there are only two real ways people access it: by enrolling in a clinical trial, or by buying unapproved "research chemical" vials online, which is the legal and safety gray market. There is no third, legitimate "get a prescription" option for an unapproved drug.

The clean route is a clinical trial. The TRIUMPH studies recruit through ClinicalTrials.gov and study sites, where the drug is supplied, dosed, and monitored under medical supervision at no cost to the participant. The other route, the research-peptide market, is where most online searches end up: vendors sell lyophilized retatrutide "for research use only," and buyers reconstitute and use it off-label. That market carries real risks of mislabeled potency, impurities, and non-sterile product, with no oversight.

If you are researching that path despite the risks, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your country and situation. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and learn to read it. See how to vet peptide quality.
3. Understand handling before anything else. Reconstitution and cold storage are not optional. See our retatrutide storage and stability guide and getting started with peptides.
4. Talk to a qualified clinician who can weigh your specific health situation, interactions, and contraindications.

We are describing what people do, not endorsing it. Using an unapproved drug outside a trial means accepting unknown risks with no regulatory safety net.

A realistic look at expectations

Trial averages are the ceiling, not the promise: real-world results depend on dose reached, how long you stay on, tolerability, and lifestyle, and many people land below the headline percentages. Going in with calibrated expectations is part of using any of this information responsibly.

Two honest caveats sit on top of the impressive numbers. First, the biggest losses came at the highest doses sustained over many months, which not everyone tolerates or reaches. Second, like other GLP-1-class drugs, stopping is associated with weight regain in the broader drug class, so these are studied as long-term, not short-term, interventions. For grounded before-and-after context and how to read transformation claims, see peptides before and after.

Frequently Asked Questions

The bottom line

Retatrutide is the most powerful weight-loss drug studied so far, and the clearest example yet of where multi-receptor metabolic medicine is heading. By activating GLP-1, GIP, and glucagon in one weekly injection, it has reported up to roughly 28-29% average weight loss in early Phase 3 trials, beyond what single- or dual-receptor drugs achieved. That is genuinely remarkable, and it is also only part of the story.

The other part is discipline: retatrutide is investigational, unapproved, and available outside trials only as an unregulated research chemical with unknown quality. The trial results were produced under medical supervision with controlled dosing and monitoring, none of which comes in a vial bought online. If you take one thing from this hub, let it be the gap between "extraordinary in trials" and "approved and safe to use at home," and the value of a qualified clinician in closing it. From here, the natural next reads are retatrutide storage and stability, are peptides legal, and how to vet peptide quality.

Sources

• Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial." New England Journal of Medicine, 2023. DOI 10.1056/NEJMoa2301972. Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
• ClinicalTrials.gov. "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight" (TRIUMPH-1, NCT05929066). Retrieved 2026-06-15. https://clinicaltrials.gov/study/NCT05929066
• Eli Lilly and Company / PR Newswire. "Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial." May 2026. Retrieved 2026-06-15. https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html
• Healio. "Retatrutide confers up to 28.7% weight loss, reduction in knee osteoarthritis pain." December 2025. Retrieved 2026-06-15. https://www.healio.com/news/endocrinology/20251211/retatrutide-confers-up-to-287-weight-loss-reduction-in-knee-osteoarthritis-pain
• HCPLive. "TRIUMPH-4: Retatrutide Delivers Weight Loss, Knee Osteoarthritis Pain Relief." December 2025. Retrieved 2026-06-15. https://www.hcplive.com/view/triumph-4-retatrutide-delivers-weight-loss-knee-osteoarthritis-pain-relief
• Noom. "Retatrutide Side Effects and Safety: What We Know." 2025. Retrieved 2026-06-15. https://www.noom.com/blog/weight-management/retatrutide-side-effects/
• GoodRx. "Retatrutide for Weight Loss: Availability, Dosage, and More." Retrieved 2026-06-15. https://www.goodrx.com/conditions/weight-loss/retatrutide-weight-loss